Repligen Corporation (NASDAQ:RGEN) was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating in a research note issued to investors on Monday.
A number of other equities analysts have also recently weighed in on RGEN. William Blair started coverage on Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating on the stock. BidaskClub cut Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $40.00 price target on shares of Repligen Corporation in a research note on Thursday, September 14th. Finally, Stephens reaffirmed an “overweight” rating and issued a $50.00 price target on shares of Repligen Corporation in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $44.67.
Shares of Repligen Corporation (NASDAQ:RGEN) traded down $1.00 during midday trading on Monday, hitting $32.53. The company had a trading volume of 556,400 shares, compared to its average volume of 323,981. The stock has a market cap of $1,460.74, a PE ratio of 57.81, a price-to-earnings-growth ratio of 2.23 and a beta of 1.05. Repligen Corporation has a 52 week low of $28.48 and a 52 week high of $46.81.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. The company had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. Repligen Corporation had a return on equity of 7.57% and a net margin of 16.93%. Repligen Corporation’s revenue for the quarter was up 48.2% compared to the same quarter last year. During the same period last year, the firm posted $0.08 EPS. equities analysts forecast that Repligen Corporation will post 0.6 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Repligen Corporation (RGEN) Stock Rating Lowered by TheStreet” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/11/15/repligen-corporation-rgen-stock-rating-lowered-by-thestreet.html.
A number of institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its stake in shares of Repligen Corporation by 113.7% during the third quarter. Cubist Systematic Strategies LLC now owns 23,288 shares of the biotechnology company’s stock valued at $892,000 after buying an additional 12,388 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Repligen Corporation during the third quarter valued at approximately $3,349,000. Cornerstone Capital Management Holdings LLC. increased its stake in shares of Repligen Corporation by 78.0% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 16,206 shares of the biotechnology company’s stock valued at $620,000 after buying an additional 7,100 shares during the period. Royce & Associates LP increased its stake in shares of Repligen Corporation by 14.5% during the third quarter. Royce & Associates LP now owns 80,149 shares of the biotechnology company’s stock valued at $3,071,000 after buying an additional 10,149 shares during the period. Finally, Allianz Asset Management GmbH increased its stake in shares of Repligen Corporation by 31.3% during the third quarter. Allianz Asset Management GmbH now owns 175,414 shares of the biotechnology company’s stock valued at $6,722,000 after buying an additional 41,842 shares during the period. 96.47% of the stock is currently owned by institutional investors and hedge funds.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.